Page 2445 - Williams Hematology ( PDFDrive )

2416 Index Index 2417

Cimetidine CLL. See Chronic lymphocytic leukemia for stroke prevention, 2076, 2297
for acute intermittent porphyria, 904 (CLL) for unstable angina, 2296
aplastic anemia and, 516 Clofarabine, 322, 324–325 Clostridial bacteremia, 2207
for toxic methemoglobinemia, 793 for acute myelogenous leukemia, 1402t Clostridium difficile, 384, 388, 1182
Ciprofloxacin, 387t, 388 for Langerhans cell histiocytosis, 1107 Clostridium perfringens, 817f, 2211
Circulating cell-free fetal DNA (ccff-DNA), for myelodysplastic syndromes, 1362 Clostridium perfringens septicemia, 819
852 resistance, 319t Closure time, in newborn, 107
Circulatory overload, transfusion-associated, structure, 323f Clot retraction, 1842
2376 Clonal disorders. See Chromosomal CLP (common lymphoid progenitor), 269–
Circumcision, 1988 abnormalities 270, 1151
CIS3 (SOCS3), 485, 486f Clonal hematopoiesis, 1284 CLPD-NK. See Chronic lymphoproliferative
Cisplatin, 331, 331t. See also ESHAP regimen Clonal hemopathy, in myelofibrosis, 1328 disorders of NK cells (CLPD-NK)
for diffuse large B-cell lymphoma, 1629t, Clonality assay, 883–884 CLRs (C-type lectin receptors), 1008, 1870–
1631 Clonally evolved acute myelogenous 1871
for Hodgkin lymphoma, 1616 leukemia (ceAML), 1281 Clustered, regularly interspaced, short
platelet function and, 2079 Clonal myeloid disorders, 1275–1287, 1276t. palindromic repeats (CRISPR), 444
secondary acute myelogenous leukemia See also specific disorders Cluster of differentiation. See under CD
and, 1407 aplastic anemia and, 521 CML. See Chronic myelogenous (myeloid)
Citrovorum factor, 584 basophilia in, 971–972, 972t leukemia (CML)
c-Kit, 258, 264–265 clinical manifestations, 1284–1287 CMML. See Chronic myelomonocytic
c-Kit ligand. See Stem cell factor (SCF) blood cell deficiency, excess, or leukemia (CMML)
CKS1B, 1712, 1736 dysfunction, 1284–1285 C-MOPP regimen, for diffuse large B-cell
CLA-1 (scavenger receptor-B1, SCARB1), extramedullary tumors, 1285 lymphoma, 1628–1629
1872 factitious laboratory results, 1287 CMP (common myeloid progenitor),
Cladribine, 324 hyperleukocytic syndromes, 1285–1286, 270–271, 1151
for acute myelogenous leukemia, 1395t, 1286t c-mpl. See Thrombopoietin (TPO) receptor
1396, 1402t marrow necrosis, 1287 (c-mpl, CD110)
for adult Langerhans cell histiocytosis, metabolic signs, 1286–1287 CMR (complete molecular response), 1452t
1108–1109 organ involvement, 1287 CMV infection. See Cytomegalovirus (CMV)
for autoimmune hemolytic anemia, 839 procoagulant and fibrinolytic activator infection
autoimmune hemolytic anemia and, 831 release, 1285 CMV mononucleosis. See Cytomegalovirus
for chronic lymphocytic leukemia, 1534, splenomegaly, 1287 (CMV) mononucleosis
1535 systemic symptoms, 1286 CMX-001, 369
for Erdheim-Chester disease, 1111 thrombocythemic syndromes, 1286 c-Myc, 237
for follicular lymphoma, 1645t interplay of clonal and polyclonal c-MYC, 230t, 235t, 1626
for gastric MALT lymphoma, 1666 hematopoiesis in, 1284 CNVs (copy number variants), 147
for hairy cell leukemia, 1553, 1557, 1559t minimal-deviation, 1276t, 1277–1278 CoA (acetyl-coenzyme A), 193, 193f, 196
with IFN-α, for mastocytosis, 977 moderate-deviation, 1276t, 1278–1279 CoA (succinyl coenzyme A), 892, 893f
for juvenile xanthogranuloma, 1112 moderately severe-deviation, 1276t, 1279 Coagulation. See also Hemostasis
for Langerhans cell histiocytosis, 1106, pathogenesis, 1281–1282, 1281f activation of, in sickle cell disease, 765
1107 Ph chromosome–positive, 1450 control of, 1949–1961, 2222f. See also
for pure red cell aplasia, 544 phenotype, 1282–1283, 1282f, 1283f Coagulation factors
resistance to, 319t pluripotential stem cell pool and, 1283 activated protein C. See Activated
structure, 323f quantitativeness, 1283–1284 protein C (APC)
for Waldenström macroglobulinemia, severe-deviation, 1276t, 1279–1280 activated protein C–independent
1793, 1794–1795 transitions among, 1280–1281 activity of protein S, 1958
Classic von Hippel-Lindau syndrome, Clone, 175t coagulation pathways. See Coagulation,
877–878 Cloning, DNA, 152 pathways
Class switching, heavy-chain, 1168–1169 Clonogenic myeloerythroid progenitors, 1154 heparin cofactor II, 1960
Class switch recombination (CSR), 1213 Clopidogrel, 405 hereditary deficiencies associated with,
Claudication, 2297 antiplatelet effects, 405, 2076 1951
CLC (Charcot-Leyden crystal) protein, 929, clinical uses, 404t, 405 inhibition of activated protein C,
947, 953 dosage, 404t 1958
Clearance receptors, 2309 for essential thrombocythemia, 1313 protease inhibitors, 1958–1959
CLEC-2, 1857, 1871 for peripheral arterial disease, 2297 protein C pathway. See Protein C
Clindamycin, for babesiosis, 819 platelet transfusion and, 2385 pathway

Kaushansky_index_p2393-2506.indd 2416 9/21/15 3:21 PM